Andere Sprachen Theravance Biopharma, Inc.

Aktien

A1137V

KYG8807B1068

TBPH

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
8,44 ^USD	-6,12 %		-8,46 %	-24,91 %

12.04.	Sektor-Update: Aktien des Gesundheitswesens geben am Freitagnachmittag nach	MT
12.04.	Theravance Biopharma-Aktien steigen, nachdem BTIG die Coverage mit Buy beginnt	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024	29.04.
Sector Update: Health Care Stocks Lower Friday Afternoon	12.04.
Theravance Biopharma Shares Rise After BTIG Starts Coverage at Buy	12.04.
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024	10.04.
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	01.03.
Theravance Bio: Q4 Earnings Snapshot	26.02.
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, vs. Street Est of $17.6M	26.02.
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	26.02.
Theravance Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.02.
Theravance Biopharma to Participate in an Upcoming Investor Conference	22.02.
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	14.02.
Theravance Biopharma Shares Drop Pre-Bell as Phase 4 Study of Lung Disease Treatment Fails to Meet Primary Endpoint	05.01.
Top Premarket Decliners	05.01.
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)	05.01.
Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease	05.01.
Theravance Biopharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed.	01.01.
Theravance Biopharma : Material Event - Form 8-K	28.12.
Theravance Biopharma Announces Appointment of Jeremy Grant to Board of Directors	21.12.
Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director	21.12.
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors	21.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Theravance Biopharma, Inc.

Aktien

A1137V

KYG8807B1068

TBPH

Andere Sprachen

Filter